KCS Wealth Advisory Takes $647,000 Position in Danaher Co. (DHR)

KCS Wealth Advisory acquired a new stake in Danaher Co. (NYSE:DHR) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,968 shares of the conglomerate’s stock, valued at approximately $647,000.

A number of other institutional investors have also made changes to their positions in the business. GQG Partners LLC bought a new position in shares of Danaher during the 2nd quarter worth $101,000. Zions Bancorporation grew its position in shares of Danaher by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after buying an additional 667 shares in the last quarter. Monetary Management Group Inc. grew its position in shares of Danaher by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after buying an additional 150 shares in the last quarter. Acrospire Investment Management LLC grew its position in shares of Danaher by 185.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after buying an additional 1,100 shares in the last quarter. Finally, Motco grew its position in shares of Danaher by 8.8% during the 2nd quarter. Motco now owns 2,011 shares of the conglomerate’s stock worth $170,000 after buying an additional 163 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Shares of Danaher Co. (DHR) traded up $0.80 during mid-day trading on Friday, reaching $99.39. The company had a trading volume of 1,875,557 shares, compared to its average volume of 2,300,000. Danaher Co. has a 12 month low of $78.97 and a 12 month high of $99.66. The company has a market capitalization of $69,140.00, a P/E ratio of 29.58, a P/E/G ratio of 2.07 and a beta of 1.03. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter last year, the company earned $0.87 earnings per share. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. sell-side analysts predict that Danaher Co. will post 3.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s payout ratio is currently 16.67%.

In related news, Director Donald J. Ehrlich sold 10,578 shares of the firm’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the sale, the director now owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Daniel Raskas sold 37,870 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by corporate insiders.

DHR has been the topic of a number of recent research reports. Morgan Stanley increased their price target on Danaher from $95.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 20th. Credit Suisse Group increased their price target on Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a research report on Thursday, October 5th. Goldman Sachs Group reissued a “neutral” rating and set a $83.00 price target on shares of Danaher in a research report on Tuesday, September 26th. Finally, Citigroup increased their price target on Danaher to $107.00 and gave the stock a “buy” rating in a research report on Friday, December 15th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $94.91.

TRADEMARK VIOLATION NOTICE: “KCS Wealth Advisory Takes $647,000 Position in Danaher Co. (DHR)” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://weekherald.com/2018/01/12/kcs-wealth-advisory-takes-647000-position-in-danaher-co-dhr.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply